Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1419 of 5804
-
Experimental combo aims to outsmart resistant lung cancer
Disease control Recruiting nowThe purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limi…
Phase: PHASE1 • Sponsor: Karen Reckamp, MD, MS • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New implant combo aims to lower eye pressure without daily drops
Disease control Recruiting nowAdult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.
Phase: PHASE4 • Sponsor: Glaukos Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Phone app aims to ease emotional burden for Alzheimer's caregivers
Symptom relief Recruiting nowAlzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) not only exact a heavy toll on patients, they also impose an enormous emotional, physical, and financial burden on unpaid, often family, caregivers. The strain of providing care for a loved one diagnosed wi…
Phase: NA • Sponsor: Bryan Denny • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail takes on tough pancreatic cancer
Disease control Recruiting nowThis is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subject…
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Personalized interferon therapy aims to tame kidney disease without weakening defenses
Disease control TerminatedMembranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 cytokine profile have a 10.5-fold increased risk of disease relapse. Interferon-ba…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New HER2-Targeting drug shows promise in early cancer trial
Disease control Recruiting nowThis study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Phase: PHASE1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can zoom mindfulness classes keep alcohol addiction at bay?
Disease control OngoingThis project will evaluate the effectiveness and mechanisms of mindfulness-based relapse prevention (MBRP) delivered via video conferencing, as compared to referral to online mutual support groups, in supporting long-term whole-person recovery and improvements in neurobiologicall…
Phase: NA • Sponsor: University of New Mexico • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental combo targets Hard-to-Treat lung cancer
Disease control OngoingThis is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Partic…
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug aims to melt liver fat in NASH patients
Disease control Recruiting nowEvaluate efficacy and safety of ADI-PEG 20 in patients with NASH
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New heart pump device aims to make risky procedures safer
Disease control OngoingThe objective is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing high-risk percutaneous interventions (HRPCI).
Phase: NA • Sponsor: Supira Medical • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Cord blood transfusions show promise for tiniest babies
Disease control CompletedThis study has been designed to demonstrate that red blood cell from umbilical cord blood (UCB-RBC) is a safe and available product for extremely preterm infants (EPI) transfusion and that transfusion of UCB-RBC is non-less effective than RBC from adult donor for the treatment of…
Phase: NA • Sponsor: Hospital Clinic of Barcelona • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Tiny needle patch takes aim at skin cancer
Disease control Recruiting nowThe purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of do…
Phase: PHASE1, PHASE2 • Sponsor: Falo, Louis, MD • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control ENROLLING_BY_INVITATIONThe main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007. The study consists of a treatment period where participants …
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental gene therapy aims to halt vision loss in rare eye disease
Disease control OngoingThe purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
App aims to boost motivation in schizophrenia patients
Symptom relief CompletedThe purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have re…
Phase: PHASE3 • Sponsor: Click Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise for tough blood cancers in early trial
Disease control CompletedThis is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recom…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New heart catheter shows promise for AFib patients
Disease control CompletedThe purpose of this study is to demonstrate safety and effectiveness of the ablation system (OMNYPULSE Bi-directional catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF…
Phase: NA • Sponsor: Biosense Webster, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Freezing device could offer new hope for sleep apnea sufferers
Disease control Recruiting nowThis is a prospective, multicenter, non-randomized single-arm safety and performance study to collect data to evaluate the safety of the Cryosa procedure to treat obstructive sleep apnea (OSA) in patients with moderate to severe OSA. The study will also evaluate the chronic perfo…
Phase: NA • Sponsor: Cryosa, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:27 UTC
-
New hope for advanced breast cancer: experimental drug FWD1802 enters human trials
Disease control Recruiting nowA Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer. This clinical trial aims to explore the role of FWD1802 in the E…
Phase: PHASE1, PHASE2 • Sponsor: Forward Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
PCOS fertility boost? supplement myo-inositol tested in major trial
Disease control Recruiting nowThe main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam cr…
Phase: PHASE3 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC